Treating cancer by blocking the interaction of tim-3 and its ligand

An anti-Gal3 antibody or a binding fragment thereof, wherein the antibody comprises:

• (1) a light chain variable region comprising a complementary determining region (CDR) L1, a CDR L2, and a CDR L3 and
• (2) a heavy chain variable region comprising a CDR H1, a CDR H2, and a CDR H3, wherein
• the CDR L1 comprises an amino acid sequence having at least about 90% identity to SEQ ID NO:17,
• the CDR L2 comprises an amino acid sequence having at least about 90% identity to SEQ ID NO:18,
• the CDR L3 comprises an amino acid sequence having at least about 90% identity to SEQ ID NO:19,
• the CDR H1 comprises an amino acid sequence having at least about 90% identity to SEQ ID NO:9,
• the CDR H2 comprises an amino acid sequence having at least about 90% identity to SEQ ID NO:10, and
• the CDR H3 comprises an amino acid sequence having at least about 90% identity to SEQ ID NO:11.

An anti-GAL3 antibody comprising:

• a heavy chain variable region comprising a sequence having at least about 90% identity to SEQ ID NO:
• 16;
• and
• a light chain variable region comprising a sequence having at least about 90% identity to SEQ ID NO:
• 24.